Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...
Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...
Dexamethasone implants improve visual and anatomical outcomes better than brolucizumab in patients with both DME and hyperreflective intraretinal dots.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback